BCAT1表达缺失是IDH突变型弥漫性胶质瘤的敏感标志物
研究对120例间变性星形细胞瘤进行BCAT1、ATRX和R132H突变型IDH1免疫组化染色,并与IDH1/IDH2 DNA测序结果相关。DNA测序显示50.8%病例有IDH1/2突变,其中73.8%为IDH1 R132H突变;BCAT1缺失见于65.8%病例,对识别IDH突变的敏感性为96.7%,对IDH1密码子132和IDH2密码子172突变的敏感性达100%。
要点
- BCAT1缺失对识别IDH突变的敏感性为96.7%。
- BCAT1缺失对IDH1密码子132和IDH2密码子172突变的敏感性达100%。
- BCAT1阳性染色可用于排除具有IDH1密码子132和IDH2密码子172突变的弥漫性胶质瘤。
核心结论
- BCAT1阳性染色可用于排除具有IDH1密码子132和IDH2密码子172突变的弥漫性胶质瘤。
- 选择BCAT1和R132H突变型IDH1染色均阴性的病例进行IDH1/2基因DNA测序,可提高检测IDH突变的成本效益,尤其在IDH突变率低的肿瘤中,并将1p/19q检测限于IDH突变肿瘤。
研究设计与样本
- 对一组120例间变性星形细胞瘤进行BCAT1、ATRX和R132H突变型IDH1免疫组化染色,染色结果与IDH1/IDH2 DNA测序结果相关。
主要发现
- DNA测序显示50.8%的病例有IDH1/2突变,其中73.8%具有IDH1 R132H突变。
- R132H突变型IDH1免疫组化染色识别了93.3%的IDH1 R132H突变和70.5%的所有IDH突变。
- BCAT1缺失见于65.8%的病例,其识别IDH突变的敏感性为96.7%。
- BCAT1缺失对IDH1密码子132和IDH2密码子172突变的敏感性达100%。
- 鉴定出若干IDH1非132密码子突变,即G97D、S122N、G123E、I130K和G131S,其预后意义不确定。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: IDH mutation is an important prognostic factor of diffuse astrocytomas. Although the majority of IDH mutations could be identified by immunohistochemical (IHC) stain for R132H-mutant IDH1, DNA sequencing would be required for IHC negative cases to determine their IDH mutation status. This approach is not cost-effective for tumors with low IDH mutation rates. OBJECTIVE: To investigate whether BCAT1 could be used as a surrogate marker for IDH mutations, because BCAT1 is an enzyme related to IDH genes. METHODS: A group of 120 anaplastic astrocytomas were immunostained for BCAT1, ATRX, and R132H-mutant IDH1. Staining results correlated with the results of DNA sequencing of IDH1/IDH2. RESULTS: DNA sequencing showed IDH1/2 mutations in 50.8% of cases of which 73.8% had IDH1 R132H mutation. Several IDH1 noncodon 132 mutations, ie, G97D, S122N, G123E, I130K, and G131S, which had uncertain prognostic significance, were identified. IHC stain for R132H-mutant IDH1 identified 93.3% of IDH1 R132H mutations and 70.5% of all IDH mutations. BCAT1 loss was seen in 65.8% of cases, its sensitivity to identify IDH mutations was 96.7%. The sensitivity reached 100% for IDH1 codon 132 and IDH2 codon 172 mutations. CONCLUSION: Positive BCAT1 stain could be used to exclude diffuse gliomas with IDH1 codon 132 and IDH2 codon 172 mutations. Selecting cases with negative BCAT1 and R132H-mutant IDH1 staining for DNA sequencing of IDH1/2 genes could improve the cost-effectiveness of detecting IDH mutations particularly in tumors with low IDH mutation rates, and confine the need of 1p/19q assay in IDH-mutant tumors.
引用
- Chen YY, Ho HL, Lin SC, et al. Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma. Neurosurgery. 2019. PMID: 30113684. doi:10.1093/neuros/nyy338
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。